INSM INSMED Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INSM

Price (delayed)

$17.24

Market cap

$2.35B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.91

Enterprise value

$2.6B

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved ...

Highlights
The company's quick ratio has surged by 58% QoQ and by 13% YoY
The company's gross profit rose by 32% YoY
The debt has soared by 117% YoY and by 60% from the previous quarter
The equity has plunged by 79% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.insmed.com
Peers: SRPT VRTX GILD ARRY

Key stats

What are the main financial stats of INSM
Market
Shares outstanding
136.41M
Market cap
$2.35B
Enterprise value
$2.6B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
26.56
Price to sales (P/S)
8.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.61
Earnings
Revenue
$245.36M
EBIT
-$453.71M
EBITDA
-$431.4M
Free cash flow
-$410.32M
Per share
EPS
-$3.91
Free cash flow per share
-$3.33
Book value per share
$0.65
Revenue per share
$1.99
TBVPS
$11.8
Balance sheet
Total assets
$1.66B
Total liabilities
$1.57B
Debt
$1.33B
Equity
$87.95M
Working capital
$1.08B
Liquidity
Debt to equity
15.08
Current ratio
6.69
Quick ratio
6.19
Net debt/EBITDA
-0.58
Margins
EBITDA margin
-175.8%
Gross margin
77.5%
Net margin
-196.3%
Operating margin
-186.4%
Efficiency
Return on assets
-39.6%
Return on equity
-867.2%
Return on invested capital
-37.3%
Return on capital employed
-30.9%
Return on sales
-184.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INSM stock price

How has the INSMED stock price performed over time
Intraday
4.74%
1 week
1.29%
1 month
-14.19%
1 year
-21.74%
YTD
-13.71%
QTD
-13.71%

Financial performance

How have INSMED's revenue and profit performed over time
Revenue
$245.36M
Gross profit
$190.23M
Operating income
-$457.32M
Net income
-$481.53M
Gross margin
77.5%
Net margin
-196.3%
The company's gross profit rose by 32% YoY
INSM's revenue is up by 30% year-on-year
INSMED's operating income has decreased by 22% YoY and by 13% QoQ
The net margin has grown by 15% YoY but it has contracted by 9% from the previous quarter

Growth

What is INSMED's growth rate over time

Valuation

What is INSMED stock price valuation
P/E
N/A
P/B
26.56
P/S
8.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.61
The EPS has declined by 7% since the previous quarter
The price to book (P/B) is 118% higher than the 5-year quarterly average of 12.2
The equity has plunged by 79% YoY
INSM's price to sales (P/S) is 65% lower than its 5-year quarterly average of 24.8 and 23% lower than its last 4 quarters average of 11.3
INSM's revenue is up by 30% year-on-year

Efficiency

How efficient is INSMED business performance
INSM's ROE has plunged by 172% from the previous quarter
The ROIC has grown by 33% year-on-year and by 6% since the previous quarter
The ROS has grown by 12% year-on-year but it has declined by 9% since the previous quarter
The company's return on assets fell by 2.1% YoY

Dividends

What is INSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INSM.

Financial health

How did INSMED financials performed over time
INSM's total assets is 6% higher than its total liabilities
INSMED's total liabilities has soared by 88% YoY and by 53% from the previous quarter
INSM's total assets has soared by 67% QoQ and by 33% YoY
The debt to equity has soared by 154% from the previous quarter
The debt has soared by 117% YoY and by 60% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.